Laboratory for Analytical Chemistry, Faculty of Pharmaceutical Sciences, Gent University, Gent, Bruges, Belgium.
Biochemistry and Immunology Laboratory, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Eur Thyroid J. 2014 Jun;3(2):109-16. doi: 10.1159/000358270. Epub 2014 May 7.
The IFCC Committee for Standardization of Thyroid Function Tests aims at equivalence of laboratory test results for free thyroxine (FT4) and thyrotropin (TSH).
This report describes the phase III method comparison study with clinical samples representing a broad spectrum of thyroid disease. The objective was to expand the feasibility work and explore the impact of standardization/harmonization in the clinically relevant concentration range.
Two sets of serum samples (74 for FT4, 94 for TSH) were obtained in a clinical setting. Eight manufacturers participated in the study (with 13 FT4 and 14 TSH assays). Targets for FT4 were set by the international conventional reference measurement procedure of the IFCC; those for TSH were based on the all-procedure trimmed mean. The manufacturers recalibrated their assays against these targets.
All FT4 assays were negatively biased in the mid- to high concentration range, with a maximum interassay discrepancy of approximately 30%. However, in the low range, the maximum deviation was approximately 90%. For TSH, interassay comparability was reasonable in the mid-concentration range, but worse in the pathophysiological ranges. Recalibration was able to eliminate the interassay differences, so that the remaining dispersion of the data was nearly entirely due to within-assay random error components. The impact of recalibration on the numerical results was particularly high for FT4.
Standardization and harmonization of FT4 and TSH measurements is feasible from a technical point of view. Because of the impact on the numerical values, the implementation needs careful preparation with the stakeholders.
国际临床化学联合会甲状腺功能检测标准化委员会旨在实现游离甲状腺素(FT4)和促甲状腺激素(TSH)实验室检测结果的等效性。
本报告描述了一项涵盖广泛甲状腺疾病谱的临床样本的 III 期方法比对研究。目的是扩展可行性工作,并探讨标准化/协调化对临床相关浓度范围内的影响。
在临床环境中获得了 74 份用于 FT4 和 94 份用于 TSH 的血清样本。共有 8 家制造商参与了该研究(FT4 有 13 种检测方法,TSH 有 14 种检测方法)。FT4 的目标值由 IFCC 的国际常规参考测量程序设定;TSH 的目标值基于所有程序修剪均值。制造商根据这些目标值对其检测方法进行重新校准。
所有 FT4 检测方法在中高浓度范围内均呈负偏倚,最大的批间差异约为 30%。然而,在低值范围内,最大偏差约为 90%。对于 TSH,在中浓度范围内,批间可比性合理,但在病理生理范围内则较差。重新校准能够消除批间差异,因此数据的剩余离散度几乎完全归因于检测内随机误差成分。重新校准对 FT4 数值结果的影响尤其大。
从技术角度来看,FT4 和 TSH 测量的标准化和协调化是可行的。由于对数值结果的影响,实施需要与利益相关者进行仔细的准备。